|
ChemicalBook Optimization Suppliers |
|
| 化学名: | | | 英語化学名: | (1R,2S)-VU0155041 | | 别名: | (1R,2S)-VU0155041;2S)-VU0155041;Cyclohexanecarboxylic acid, 2-[[(3,5-dichlorophenyl)amino]carbonyl]-, (1R,2S)-;(1R,2S)VU0155041,(1R,2S) VU0155041,(1R,2S)-VU-0155041;(1R,2S)-VU0155041, 10 mM in DMSO | | CAS番号: | 1263273-14-8 | | 分子式: | C14H15Cl2NO3 | | 分子量: | 316.18 | | EINECS: | | | カテゴリ情報: | | | Mol File: | 1263273-14-8.mol |  |
| 沸点 | 540.2±50.0 °C(Predicted) | | 比重(密度) | 1.429±0.06 g/cm3(Predicted) | | 貯蔵温度 | Store at -20°C | | 溶解性 | DMSO: ≥ 59 mg/mL (186.60 mM) | | 外見 | Solid | | 酸解離定数(Pka) | 4.48±0.44(Predicted) | | 色 | White to off-white |
| | (1R,2S)-VU0155041 Usage And Synthesis |
| 使用 | (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM. | | in vivo | VU0155041 is soluble in an aqueous vehicle and intracerebroventricular administration of 31 to 316 nM of VU0155041 dose-dependently decreases haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041, at doses of 31 and 92 nmol, is also able to significantly decrease the cataleptic effects of haloperidol, and the effects of the compound are still present 30 min after infusion. Icv infusion of a 316 nmol dose of VU0155041 also results in a significant reversal of akinesia[1]. | | IC 50 | mGluR4 | | 参考文献 | [1] Niswender CM, et al. Discovery, characterization, and antiparkinsonian effect of novel positiveallosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov;74(5):1345-58. DOI:10.1124/mol.108.049551 |
|